KIR2DL1: A Promising Drug Target Or Biomarker for Cancer (G3802)

Target Name: KIR2DL1

NCBI ID: G3802

KIR2DL1: A Promising Drug Target Or Biomarker for Cancer

The KIR2DL1 gene is a member of the human major histocompatibility complex (MHC) class I region, which is a genetic framework that plays a crucial role in the immune system. The MHC is a complex of genes that are involved in the presentation of antigens to T cells, which are critical for cell-mediated immunity.

KIR2DL1 is a non-coding RNA molecule that is expressed in many different tissues and cells, including natural killer (NK) cells, which are a type of immune cell that play a critical role in protecting the body against infection and disease. NK cells are able to recognize and destroy infected or abnormal cells without being regulated by the immune system.

KIR2DL1 is characterized by its ability to interact with the protein PD-L1, which is a negative regulator of the immune response. PD-L1 is produced by T cells in response to antigen stimulation and can inhibit the activity of NK cells. KIR2DL1 has been shown to be able to inhibit the activity of PD-L1 and increase the activity of NK cells, making it a potential drug target or biomarker for cancer and other immune-related diseases.

In addition to its potential as a drug target, KIR2DL1 has also been shown to be a potential biomarker for cancer. Several studies have shown that KIR2DL1 levels are elevated in various types of cancer, including lung cancer, breast cancer, and colon cancer. This suggests that KIR2DL1 may be a useful diagnostic or predictive marker for these diseases.

Furthermore, KIR2DL1 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression. For example, studies have shown that KIR2DL1 can promote the growth and survival of cancer cells, and that it can also inhibit the production of cell cycle proteins that are critical for the development of cancer.

In conclusion, the KIR2DL1 gene is a promising drug target or biomarker for cancer and other immune-related diseases. Its ability to interact with PD-L1 and its potential as a diagnostic or predictive marker make it a promising candidate for further study. Further research is needed to fully understand the role of KIR2DL1 in cancer and other immune-related diseases.

Protein Name: Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1

Functions: Receptor on natural killer (NK) cells for some HLA-C alleles such as w4 and w6. Inhibits the activity of NK cells thus preventing cell lysis

More Common Targets